Protara Therapeutics, Inc. (FRA:1KPA)

Germany flag Germany · Delayed Price · Currency is EUR
4.200
+0.060 (1.45%)
At close: Jan 16, 2026
-2.78%
Market Cap319.34M +45.2%
Revenue (ttm)n/a
Net Income-45.09M
EPS-1.18
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume162
Open4.200
Previous Close4.140
Day's Range4.200 - 4.200
52-Week Range2.260 - 6.500
Betan/a
RSI65.03
Earnings DateMar 9, 2026

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Jesse Shefferman
Employees 33
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1KPA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements